BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27544588)

  • 1. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
    Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
    Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of potent inhibitors of the lysophospholipase autotaxin.
    Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
    Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of a pipemidic acid autotaxin inhibitor.
    Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
    J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
    Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
    J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
    Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
    Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
    Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
    J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent research advances in ATX inhibitors: An overview of primary literature.
    Zhang C; Liu Y; Zhou Q; Fan H; Liu X; Hu J
    Bioorg Med Chem; 2023 Jul; 90():117374. PubMed ID: 37354726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif.
    Fells JI; Lee SC; Norman DD; Tsukahara R; Kirby JR; Nelson S; Seibel W; Papoian R; Patil R; Miller DD; Parrill AL; Pham TC; Baker DL; Bittman R; Tigyi G
    FEBS J; 2014 Feb; 281(4):1017-28. PubMed ID: 24314137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
    Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
    Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
    Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
    J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Function and biological activities of the autotaxin-LPA axis].
    Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
    Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Design of a Novel Class of Autotaxin Inhibitors Based on Endogenous Allosteric Modulators.
    Clark JM; Salgado-Polo F; Macdonald SJF; Barrett TN; Perrakis A; Jamieson C
    J Med Chem; 2022 Apr; 65(8):6338-6351. PubMed ID: 35440138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
    Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
    Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
    Fells JI; Lee SC; Fujiwara Y; Norman DD; Lim KG; Tsukahara R; Liu J; Patil R; Miller DD; Kirby RJ; Nelson S; Seibel W; Papoian R; Parrill AL; Baker DL; Bittman R; Tigyi G
    Mol Pharmacol; 2013 Sep; 84(3):415-24. PubMed ID: 23793291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
    Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
    Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
    Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
    J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
    Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
    J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of boronic acid based inhibitors of autotaxin.
    Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
    J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.